Financial Analysis: IntelGenx Technologies (IGXT) & OncoSec Medical (ONCS)

IntelGenx Technologies (OTCMKTS:IGXT) and OncoSec Medical (NASDAQ:ONCS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, valuation, dividends, institutional ownership and analyst recommendations.

Insider & Institutional Ownership

0.0% of IntelGenx Technologies shares are held by institutional investors. Comparatively, 11.5% of OncoSec Medical shares are held by institutional investors. 18.2% of IntelGenx Technologies shares are held by insiders. Comparatively, 7.6% of OncoSec Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares IntelGenx Technologies and OncoSec Medical’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
IntelGenx Technologies -325.81% -443.21% -73.76%
OncoSec Medical N/A -151.71% -123.34%

Earnings & Valuation

This table compares IntelGenx Technologies and OncoSec Medical’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
IntelGenx Technologies $5.20 million 12.22 -$3.05 million ($0.04) -17.00
OncoSec Medical N/A N/A -$39.13 million N/A N/A

IntelGenx Technologies has higher revenue and earnings than OncoSec Medical.

Volatility & Risk

IntelGenx Technologies has a beta of 2.21, suggesting that its share price is 121% more volatile than the S&P 500. Comparatively, OncoSec Medical has a beta of 2.41, suggesting that its share price is 141% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for IntelGenx Technologies and OncoSec Medical, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IntelGenx Technologies 0 0 2 0 3.00
OncoSec Medical 0 2 2 0 2.50

IntelGenx Technologies presently has a consensus price target of $2.00, indicating a potential upside of 194.12%. OncoSec Medical has a consensus price target of $4.00, indicating a potential upside of 516.43%. Given OncoSec Medical’s higher probable upside, analysts plainly believe OncoSec Medical is more favorable than IntelGenx Technologies.

About IntelGenx Technologies

IntelGenx Technologies Corp., a drug delivery company, focuses on the development of novel oral immediate-release and controlled-release products for the pharmaceutical market. It offers RIZAPORT, an oral thin film formulation of rizatriptan benzoate for the treatment of acute migraines. The company's products under development comprise INT0001/2004, an anti-hypertension drug; INT0004/2006, an antidepressant; INT0007/2006 for the treatment of erectile dysfunction; INT0008/2007 for migraine; INT0010/2006 for the treatment of neuropathic pain and nausea in cancer patients; INT0027/2011 to treat opioid dependence; INT0036/2013 for schizophrenia; and INT0043/2015 to treat Alzheimer's disease. It is also developing INT0037/2013, INT0039/2013, INT0040/2014, INT0042/2015, INT0043/2015, and INT0044/2016 The company has co-development and commercialization agreements with RedHill Biopharma Ltd., Par Pharmaceutical Companies, Inc., and Endo Ventures Ltd.; licensing, development, and supply agreement with Chemo Group; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.

About OncoSec Medical

OncoSec Medical Incorporated, a biotechnology company, engages in developing DNA-based intratumoral immunotherapies in the United States. The company's investigational technology, ImmunoPulseis designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as plasmid encoded IL-12 (tavokinogene telseplasmid or tavo) for the treatment of cancer. Its lead product candidate, ImmunoPulse IL-12, has demonstrated a favorable safety profile, evidence of anti-tumor activity in the treatment of various solid tumors, and the potential to reach beyond the site of local treatment to initiate a systemic immune response in Phase 1 and 2 clinical trials for metastatic melanoma and triple-negative breast cancer. The company has also completed Phase II studies in metastatic melanoma (OMS-I100) and merkel cell carcinoma (OMS-I110). OncoSec Medical Incorporated has an investigator-sponsored clinical trial with the University of California, San Francisco to evaluate the safety and efficacy of ImmunoPulse IL-12 in combination with KEYTRUDA (pembrolizumab) in patients with low tumor-infiltrating lymphocyte (OMS-I102); and a clinical trial collaboration and drug supply agreement with Merck (known as MSD outside the United States and Canada) to evaluate the combination of its ImmuoPulse IL-12 with Merck's anti-PD-1 therapy KEYTRUDA (pembrolizumab) in a registration-directed Phase 2b clinical trial referred to as PISCES. This trial would evaluate the combination of therapies in patients with unresectable metastatic melanoma who have progressed. It also has a research collaboration with Avacta Group plc for gene delivery of therapeutic affimers. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was incorporated in 2008 and is headquartered in San Diego, California.

Receive News & Ratings for IntelGenx Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IntelGenx Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit